Results 151 to 160 of about 189,117 (342)
ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger +15 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul +13 more
wiley +1 more source
Role of Bradykinin in Anaphylactoid Reactions during Hemodialysis with AN69 Dialyzers [PDF]
, 1993 Barkhausen, Regina +5 more
core +1 more source
Response to Uncritical Acceptance of Combination Treatment of Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor in Nondiabetic Renal Disease Trial Results [PDF]
, 2008 Norman M. Kaplan
openalex +1 more source
Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022
ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié +5 more
wiley +1 more source